(Albany, United States) As per DelveInsight’s assessment, globally, the Hypovolemia Pipeline constitutes 10+ key companies continuously working towards developing 10+ Hypovolemia Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Hypovolemia Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Hypovolemia NDA approvals (if any), and product development activities comprising the technology, Hypovolemia collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

To explore more information on the latest breakthroughs in the Hypovolemia Pipeline treatment landscape of the report, click here @ Hypovolemia Pipeline Outlook

 

Key Takeaways from the Hypovolemia Pipeline Report

• DelveInsight’s Hypovolemia Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline treatment therapies.
• The leading companies working in the Hypovolemia Market include Vivacelle Bio, Regeneron Pharmaceuticals, Pharmazz Inc., Otsuka Beijing Research Institute, Boehringer Ingelheim, Baxter Healthcare Corporation, Medtronic, Cheetah Medical Inc., B. Braun Melsungen AG, and others.
• Promising Hypovolemia Pipeline Therapies in the various stages of development include Volulyte 6%, Ionolyte, Gelaspan 4%, Gelofusine 4%,  Plasma-Lyte 148®, VBI-S, Empagliflozin, Dipeptidyl-peptidase 4 (DPP-4) inhibitors, Tolvaptan, Centhaquine, and others.
• On August 2023, Fresenius Kabi announced a study of phase 4 clinical trials for Volulyte 6% and Ionolyte. The aim of the study is to investigate the safety of a 6% HES (Hydroxyethyl Starch) solution (Volulyte 6%) versus an electrolyte solution (Ionolyte) in patients undergoing elective abdominal surgery.
• On August 2023, The George Institute announced a study of phase 4 clinical trials for Plasma-Lyte 148® and 0.9% sodium chloride. The aim of PLUS is to conduct a multi-centre, blinded, randomised, controlled trial (RCT) to determine whether fluid resuscitation and therapy with a “balanced” crystalloid solution (Plasma-Lyte 148®) decreases 90-day mortality in critically ill patients requiring fluid resuscitation when compared with the same treatment using 0.9% sodium chloride (saline).

 

Hypovolemia Overview

Hypovolemia is a state of an abnormally decreased volume of circulating fluid (plasma) in the body. It may be caused by a rapid and substantial loss of blood or from dehydration due to vomiting, diarrhea, burns, severe environmental fluid losses, or drugs such as diuretics.

 

For further information, refer to the detailed Hypovolemia Unmet Needs, click here for Hypovolemia Ongoing Clinical Trial Analysis

 

Hypovolemia Emerging Drugs Profile

• VBI-S: Vivacelle Bio

 

Hypovolemia Pipeline Therapeutics Assessment

There are approx. 10+ key companies which are developing the therapies for Hypovolemia. The Hypovolemia companies which have their Hypovolemia drug candidates in the most advanced stage, i.e. phase II include, Vivacelle Bio.

 

Request a sample and discover the recent advances in Hypovolemia Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Hypovolemia Segmentation

 

Hypovolemia Drugs and Companies

• Volulyte 6%: Fresenius Kabi
• Ionolyte: B. Braun Melsungen AG
• Gelaspan 4%: B. Braun Medical LLC

 

Hypovolemia Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Hypovolemia Therapeutics Market include-

Vivacelle Bio, Regeneron Pharmaceuticals, Pharmazz Inc., Otsuka Beijing Research Institute, Boehringer Ingelheim, Baxter Healthcare Corporation, Medtronic, Cheetah Medical Inc., B. Braun Melsungen AG, and others.

 

Dive deep into rich insights for drugs for the Hypovolemia Pipeline, Click here @ Hypovolemia Unmet Needs and Analyst Views

 

Scope of the Hypovolemia Pipeline Report

• Coverage- Global
• Companies- Vivacelle Bio, Regeneron Pharmaceuticals, Pharmazz Inc., Otsuka Beijing Research Institute, Boehringer Ingelheim, Baxter Healthcare Corporation, Medtronic, Cheetah Medical Inc., B. Braun Melsungen AG, and others.
• Therapies- Volulyte 6%, Ionolyte, Gelaspan 4%, Gelofusine 4%,  Plasma-Lyte 148®, VBI-S, Empagliflozin, Dipeptidyl-peptidase 4 (DPP-4) inhibitors, Tolvaptan, Centhaquine, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Hypovolemia Merger and acquisitions, Licensing Activities

 

Table of Content

1. Introduction
2. Executive Summary
3. Hypovolemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Hypovolemia – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Hypovolemia Collaboration Deals
9. Late Stage Products (Phase III)
10. Drug Name: Company Name
11. Mid Stage Products (Phase II)
12. VBI-S: Vivacelle Bio
13. Drug profiles in the detailed report…..
14. Early Stage Products (Phase I)
15. Drug Name: Company Name
16. Drug profiles in the detailed report…..
17. Pre-clinical and Discovery Stage Products
18. Drug Name: Company Name
19. Drug profiles in the detailed report…..
20. Inactive Products
21. Hypovolemia Key Companies
22. Hypovolemia Key Products
23. Hypovolemia- Unmet Needs
24. Hypovolemia- Market Drivers and Barriers
25. Hypovolemia- Future Perspectives and Conclusion
26. Hypovolemia Analyst Views
27. Hypovolemia Key Companies
28. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services